Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHP2302R1 + DHP2302R2
- Development stage
- Unknown
- Lead developer
- Daehwa Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DHP2302R1 + DHP2302R2 is a **combination of two investigational small molecule drugs** developed by DAE HWA PHARM. This combination is currently in early clinical development, specifically designed for **pharmacokinetic and drug-drug interaction studies** in healthy volunteers. The precise mechanisms of action, molecular targets, and therapeutic indications have not been disclosed in public sources as of the latest available data. Both constituents, DHP2302R1 and DHP2302R2, are being evaluated in combination to assess their safety profiles and interaction properties in humans as part of Phase 1 clinical trials.
- Other names
- DHP2302R1DHP-2302R1DHP 2302R1DHP2302R2DHP-2302R2DHP 2302R2
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on DHP2302R1 + DHP2302R2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHP2302R1 + DHP2302R2.